Aclaris Therapeutics Announces $80 Million Private Placement
Aclaris Therapeutics (NASDAQ: ACRS) has secured a $80 million private placement through the sale of 35,555,555 shares of common stock at $2.25 per share. The placement was led by Vivo Capital, with participation from both new and existing investors including Forge Life Science Partners, Rock Springs Capital, and RA Capital Management, among others. The transaction is expected to close around November 19, 2024. The proceeds will be used to fund research and development of the company's pipeline and general corporate purposes. The company has agreed to file a registration statement with the SEC for the resale of the shares.
Aclaris Therapeutics (NASDAQ: ACRS) ha ottenuto un collocamento privato di 80 milioni di dollari tramite la vendita di 35.555.555 azioni ordinarie a 2,25 dollari per azione. Il collocamento è stato guidato da Vivo Capital, con la partecipazione di investitori sia nuovi che esistenti, tra cui Forge Life Science Partners, Rock Springs Capital e RA Capital Management, tra gli altri. Si prevede che la transazione si concluda intorno al 19 novembre 2024. I proventi saranno utilizzati per finanziare la ricerca e lo sviluppo della pipeline dell'azienda e per finalità aziendali generali. L’azienda ha concordato di presentare una dichiarazione di registrazione alla SEC per la rivendita delle azioni.
Aclaris Therapeutics (NASDAQ: ACRS) ha asegurado un colocación privada de 80 millones de dólares a través de la venta de 35,555,555 acciones ordinarias a 2,25 dólares por acción. La colocación fue liderada por Vivo Capital, con la participación de inversores tanto nuevos como existentes, incluyendo a Forge Life Science Partners, Rock Springs Capital y RA Capital Management, entre otros. Se espera que la transacción se cierre alrededor del 19 de noviembre de 2024. Los ingresos se utilizarán para financiar la investigación y el desarrollo de la cartera de productos de la compañía y para fines corporativos generales. La empresa ha acordado presentar una declaración de registro ante la SEC para la reventa de las acciones.
Aclaris Therapeutics (NASDAQ: ACRS)는 35,555,555주를 주당 2.25달러에 판매하여 8000만 달러의 사모투자를 확보했습니다. 이 투자 주관사는 Vivo Capital이며, Forge Life Science Partners, Rock Springs Capital, RA Capital Management 등 신생 및 기존 투자자들이 참여했습니다. 이 거래는 2024년 11월 19일경에 마무리될 것으로 예상됩니다. 수익금은 회사의 연구 개발 및 일반 기업 활동을 위한 자금으로 사용됩니다. 회사는 주식 재판매를 위해 SEC에 등록신청서를 제출하기로 합의했습니다.
Aclaris Therapeutics (NASDAQ: ACRS) a sécurisé un placement privé de 80 millions de dollars par la vente de 35 555 555 actions ordinaires à 2,25 dollars par action. Le placement a été dirigé par Vivo Capital, avec la participation d'investisseurs nouveaux et existants, y compris Forge Life Science Partners, Rock Springs Capital et RA Capital Management, parmi d'autres. La transaction devrait se clôturer aux alentours du 19 novembre 2024. Les fonds seront utilisés pour financer la recherche et le développement du pipeline de l'entreprise ainsi que pour des fins d'entreprise générales. L'entreprise a accepté de déposer une déclaration d'enregistrement auprès de la SEC pour la revente des actions.
Aclaris Therapeutics (NASDAQ: ACRS) hat eine 80 Millionen Dollar Private Placement durch den Verkauf von 35.555.555 Stammaktien zu je 2,25 Dollar pro Aktie gesichert. Die Platzierung wurde von Vivo Capital geleitet, mit Teilnahme von neuen sowie bestehenden Investoren, darunter Forge Life Science Partners, Rock Springs Capital und RA Capital Management, unter anderem. Die Transaktion wird voraussichtlich um den 19. November 2024 abgeschlossen sein. Die Erlöse werden für die Finanzierung von Forschung und Entwicklung der Produktpipeline des Unternehmens sowie für allgemeine Unternehmenszwecke verwendet. Das Unternehmen hat zugestimmt, eine Registrierungserklärung bei der SEC für den Wiederverkauf der Aktien einzureichen.
- Secured $80 million in additional funding
- Attracted participation from multiple prominent healthcare investors
- Strengthened cash position for R&D pipeline advancement
- Share dilution for existing stockholders
- Below-market pricing at $2.25 per share
Insights
This
The funding provides important runway for advancing their immuno-inflammatory disease pipeline. Notable is the registration rights agreement, which will allow these shares to become freely tradeable once registered with the SEC. However, potential dilution from issuing 35.5M new shares could pressure the stock price in the near term. The caliber of participating investors suggests strong institutional confidence in Aclaris's clinical programs and long-term potential.
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of
The private placement was led by Vivo Capital, with participation by new and existing investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital and Samsara BioCapital.
Net proceeds from the private placement are expected to fund the research and development of its pipeline and for general corporate purposes.
The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale of the shares of common stock sold in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
Leerink Partners and Cantor acted as placement agents in connection with the private placement.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include statements regarding the closing of the private placement and anticipated use of proceeds. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to, risks related to market conditions and the satisfaction of closing conditions for the private placement, uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2023, and other filings Aclaris makes with the SEC from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contact:
investors@aclaristx.com
FAQ
How much did Aclaris Therapeutics (ACRS) raise in their November 2024 private placement?
Who were the lead investors in Aclaris Therapeutics (ACRS) November 2024 private placement?
What will Aclaris Therapeutics (ACRS) use the private placement proceeds for?
When is the Aclaris Therapeutics (ACRS) private placement expected to close?
